Silo Pharma To Patent Novel Ketamine-Based Treatment For Chronic Condition

Biopharma company Silo Pharma Inc. SILO filed a provisional patent application to the US Patent and Trading Office covering “methods and compositions for pain management” towards ameliorating pain, including chronic pain such as fibromyalgia, with its SP-26 program using a proprietary ketamine composition.

Fibromyalgia is a chronic condition causing pain to the connective tissues including muscles, ligaments and tendons, often associated with sleep difficulties, fatigue, mood disorders, and problems with memory and concentration. It affects nearly 2% of the total U.S. population.

See Also: Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing

Silo Pharma’s novel drug candidate initially targets this indication, yet the provisional patent application supports the company’s “multi-pronged strategy” for advancing SP-26 into the clinic.

Silo CEO Eric Weisblum is working towards submitting an IND package to the FDA and pursuing the 505(b)(2) regulatory pathway for its drug candidate.

“We believe our drug would serve a critical need in a largely inadequate treatment landscape for chronic pain including fibromyalgia,” he concluded.

See Also: Psychedelic Trials Update - Treating Meth Addiction, Fibromyalgia & General Anxiety Disorder

Furthermore, the Company’s IP and technology rights for the treatment of rare diseases span over six issued and provisional patents, with additional patent applications pending. 

Benzinga’s PCC

The second edition of the Benzinga Psychedelics Capital Conference is inching closer each day! 

The event will take place at the Fontainebleau Miami Beach Hotel in Florida on April 13, 2023. This is THE place to get DEALS DONE, raise money, jumpstart M&A and meet investors and key partners.

Get your tickets now before prices go up!

Photo by Julia Koblitz on Unsplash